A retrospective analysis of triptan and dhe use for basilar and hemiplegic migraine.
CONCLUSION: In this retrospective study, triptans and DHE were used with no reported, subsequent acute/subacute ischemic vascular events for the abortive treatment of migraines with basilar and hemiplegic-type features. Although the small sample sizes generated theoretical statistical event rates of 4.5% for BM and 23% for HM, there has been no clear evidence that BM and HM carry an actual elevated risk for vascular events compared with migraine with aura.
PMID: 27062528 [PubMed - as supplied by publisher]
Source: Headache - Category: Neurology Authors: Mathew PG, Krel R, Buddhdev B, Ansari H, Joshi SG, Spinner WD, Klein BC Tags: Headache Source Type: research
More News: Aphasia | Ataxia | Clinical Trials | Dystonia | Headache | Heart Attack | Ischemic Stroke | Migraine | Neurology | Statistics | Stroke | Study | Vertigo